On The Radar – 20th Edition
By
The Department of Labor is intensifying enforcement against plan sponsors and partners who fail to act in the best interest of members, with a sharp focus on hidden financial incentives and opaque contracts.
➡ Why it matters: Fiduciary responsibility is no longer theoretical. It is being actively enforced.
Pharma companies are investing in patient advocacy models that go beyond access, creating loyalty through support programs and navigation tools that shape the entire treatment journey.
➡ Why it matters: The patient experience is becoming a competitive advantage, not just the medication itself.
New transparency rules are giving employers deeper insight into PBM pricing, but also removing the ability to claim ignorance when costs are mismanaged.
➡ Why it matters: Visibility brings accountability and increased legal exposure.
Advocacy groups are pushing lawmakers to address PBM practices, focusing on rebate structures, formulary control, and vertical integration across the supply chain.
➡ Why it matters: Reform momentum continues to build from both policy and clinical stakeholders.
Stop-loss carriers are increasingly “lasering” high-cost members, pushing more financial exposure onto self-funded plans as specialty drug costs rise.
➡Why it matters: Predictable high-cost claims are becoming the employer’s problem to solve.
Expanded federal requirements are forcing PBMs to disclose detailed compensation structures, including rebates and administrative fees that were previously hidden.
➡Why it matters: Employers now have the tools to understand where every dollar is going.
Employers are shifting focus from talent-driven benefits strategies to managing the financial sustainability of healthcare programs as costs continue to rise.
➡Why it matters: Benefits strategy is being redefined by cost pressure, not competition for talent.
Healthcare M&A activity is surging, with vertical integration expanding across insurers, PBMs, and providers, reshaping the competitive landscape.
➡ Why it matters: Fewer, larger players can mean less competition and greater pricing power.
A growing share of Americans are making financial trade-offs just to maintain health coverage, highlighting the widening gap between access and affordability.
➡ Why it matters: Coverage alone no longer guarantees affordability or access to care.
Large organizations are moving toward direct contracting and transparent pricing models, taking a more active role in healthcare purchasing.
➡ Why it matters: Employers are shifting from passive payers to active buyers.
Policymakers are accelerating efforts to expand biosimilar competition as a way to reduce the cost of high-priced biologic therapies.
➡ Why it matters: Competition remains one of the most effective levers for cost control.
A handful of pharmaceutical giants continue to dominate the market, fueled by breakthrough therapies and aggressive expansion strategies.
➡ Why it matters: Market concentration continues to influence pricing, access, and innovation.
Transparent, cost-plus pharmacy models are gaining traction, challenging traditional PBM structures and reshaping how patients access medications.
➡ Why it matters: Pricing transparency is no longer hypothetical. It is showing up in real alternatives.
AI is becoming embedded across drug development and manufacturing, helping reduce timelines, improve efficiency, and reshape supply chains.
➡ Why it matters: Technology is accelerating innovation while redefining operational strategy.
Proposed legislation aims to ensure all prescription purchases count toward deductibles, aligning benefit design with how patients actually access medications.
➡ Why it matters: The system is slowly adapting to meet patients where they are, not where contracts assume they should be.
Final Thoughts
Transparency is exposing how the system really works, and enforcement is making it matter.
At the same time, innovation, consolidation, and new care models are reshaping how medications are accessed and delivered. For employers, the path forward requires active management, not passive participation.
We’ll be back in two weeks with more news you need to know. If you’d like a custom analysis or want to explore SHARx program options for your clients, contact us!
Stay Connected with SHARx
Subscribe to our newsletter for monthly updates from our CEO, curated industry news, insights from our in-house pharmacist, the latest blog posts, and more. Just fill out the form to stay informed.
Newsletter Sign-up
Be the first to learn what’s new with SHARx.